Table 2.
Proportion of sample use for selected study drugs with the highest projected sample use during the last 5 calendar years of market exclusivity
| Rosuvastatin (2009–2013) |
Sitagliptin (2009–2013) |
Exenatide (2009–2013) |
Losartan (2005–2009) |
Dabigatran (2010–2013) |
||||||
|---|---|---|---|---|---|---|---|---|---|---|
| New | Cont | New | Cont | New | Cont | New | Cont | New | Cont | |
| Visitsa (n × 1000) | 10,937 | 16,779 | 3645 | 4764 | 905 | 1077 | 3064 | 7471 | 1217 | 944 |
| Sample only | 8.6 | 4.7 | 9.9 | 3.7 | >3.0b | >3.0b | 12.8 | 5.8 | 15.0 | 10.5 |
| Sample + Rx | 39.9 | 19.3 | 34.8 | 13.3 | 29.1 | >3.0b | 32.2 | 12.0 | 28.5 | 12.2 |
| Sample any | 48.5 | 23.9 | 44.7 | 17.0 | 38.1 | 9.8 | 45.0 | 17.8 | 43.5 | 22.7 |
| Sample days, weighted average | 17.8 | 18.9 | 17.2 | 24.5 | 22.8 | 25.3 | 18.6 | 19.7 | 13.4 | 14.7 |
| Insurance type, % sample any | ||||||||||
| Private | 45.3 | 20.8 | 31.1 | 23.1 | >3.0b | >3.0b | 56.2 | 9.1 | >3.0b | >3.0b |
| HMO | 50.7 | 24.0 | 59.2 | >3.0b | >3.0b | >3.0b | >3.0b | 15.4 | >3.0b | >3.0b |
| PPO | 61.7 | 24.6 | 48.9 | 13.0 | >3.0b | >3.0b | 44.2 | >3.0b | >3.0b | <3.0b |
| Medicare Part D | 41.3 | 22.6 | 53.4 | 15.5 | >3.0b | >3.0b | 58.8 | 31.7 | 51.0 | 23.2 |
| Medicaid | 27.2 | 26.8 | 30.0 | >3.0b | >3.0b | >3.0b | >3.0b | >3.0b | >3.0b | <3.0b |
| No insurance | >3.0b | >3.0b | >3.0b | >3.0b | <3.0b | <3.0b | >3.0b | >3.0b | >3.0b | >3.0b |
| Moxifloxacin, oral (2009–2013) |
Moxifloxacin, ophthalmic (2009–2013) |
Atomoxetine (2009–2013) |
Drospirenone/EE (2008–2012) |
Norethindrone/EE/fe (2006–2010) |
||||||
|---|---|---|---|---|---|---|---|---|---|---|
| New | Cont | New | Cont | New | Cont | New | Cont | New | Cont | |
| Visitsa (n × 1000) | 12,117 | 255 | 11,989 | 369 | 1048 | 2139 | 6634 | 12,145 | 7288 | 6710 |
| Sample only | 10.0 | >3.0b | 8.2 | >3.0b | 13.4 | >3.0b | 16.6 | 4.7 | 24.7 | 17.6 |
| Sample + Rx | 14.4 | >3.0b | 5.8 | <3.0b | 14.3 | 10.5 | 43.3 | 35.9 | 56.8 | 45.1 |
| Sample any | 24.3 | >3.0b | 14.0 | >3.0b | 27.7 | 14.4 | 59.9 | 40.6 | 81.5 | 62.7 |
| Sample days, weighted average | 4.8 | 4.9 | 5.8 | 6.8 | 21.1 | 15.5 | 44.6 | 41.2 | 47.1 | 41.9 |
| Insurance type, % sample any | ||||||||||
| Private | 15.2 | >3.0b | 17.9 | >3.0b | 40.0 | 25.9 | 61.5 | 42.7 | 87.4 | 73.1 |
| HMO | 17.0 | >3.0b | 13.7 | >3.0b | >3.0b | >3.0b | 56.0 | 43.8 | 79.5 | 57.4 |
| PPO | 32.9 | >3.0b | 13.8 | >3.0b | >3.0b | >3.0b | 62.0 | 38.4 | 80.9 | 59.5 |
| Medicare part D | 35.6 | >3.0b | >3.0b | >3.0b | >3.0b | >3.0b | >3.0b | <3.0b | >3.0b | >3.0b |
| Medicaid | 14.2 | >3.0b | 10.0 | <3.0b | >3.0b | >3.0b | 63.1 | >3.0b | 74.3 | 68.9 |
| No insurance | 55.5 | >3.0b | 11.9 | >3.0b | >3.0b | >3.0b | >3.0b | >3.0b | 85.4 | >3.0b |
Data are presented as % unless otherwise indicated. Sample only refers to provision of a sample without accompanying prescription, sample + Rx refers to the provision of a sample together with a prescription for the same drug, and sample any is the sum of sample only and sample + Rx. Data Source: Encuity Research, LLC, TreatmentAnswersTM Audit. Extracted June 2014
Cont continued use, EE ethinyl estradiol, HMO health maintenance organization, PPO preferred provider organization, Rx prescription
Visits during which prescription was issued and/or sample was provided for drug of interest
Based on fewer than 100,000 projected counts